Susan Bobulsky has served as Adaptive Biotechnologies' Chief Commercial Officer, MRD since January 2024, leading the commercial organization for the clonoSEQ minimal residual disease franchise. She served in commercial and strategic planning roles of ascending responsibility after joining Adaptive in September 2014. Before Adaptive she spent nine years as an Associate Principal with ZS Associates, a healthcare management consulting firm, specializing in commercialization strategy and execution for therapeutic and diagnostic products. Ms. Bobulsky holds an MBA from the Stanford Graduate School of Business and a BS in Science, Technology and Society from Stanford University.